PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS ONE. 2009; 4(3): e4733.
Published online 2009 March 6. doi:  10.1371/journal.pone.0004733
PMCID: PMC2649379

Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques

Jeffrey S. Berger, Editor

Abstract

Background

Atherosclerosis is the primary cause of coronary artery disease (CAD). There is increasing recognition that lesion composition rather than size determines the acute complications of atherosclerotic disease. Low serum adiponectin levels were reported to be associated with coronary artery disease and future incidence of acute coronary syndrome (ACS). The impact of adiponectin on lesion composition still remains to be determined.

Methodology/Principal Findings

We measured serum adiponectin levels in 303 patients with stable typical or atypical chest pain, who underwent dual-source multi-slice CT-angiography to exclude coronary artery stenosis. Atherosclerotic plaques were classified as calcified, mixed or non-calcified. In bivariate analysis adiponectin levels were inversely correlated with total coronary plaque burden (r = −0.21, p = 0.0004), mixed (r = −0.20, p = 0.0007) and non-calcified plaques (r = −0.18, p = 0.003). No correlation was seen with calcified plaques (r = −0.05, p = 0.39). In a fully adjusted multivariate model adiponectin levels remained predictive of total plaque burden (estimate: −0.036, 95%CI: −0.052 to −0.020, p<0.0001), mixed (estimate: −0.087, 95%CI: −0.132 to −0.042, p = 0.0001) and non-calcified plaques (estimate: −0.076, 95%CI: −0.115 to −0.038, p = 0.0001). Adiponectin levels were not associated with calcified plaques (estimate: −0.021, 95% CI: −0.043 to −0.001, p = 0.06). Since the majority of coronary plaques was calcified, adiponectin levels account for only 3% of the variability in total plaque number. In contrast, adiponectin accounts for approximately 20% of the variability in mixed and non-calcified plaque burden.

Conclusions/Significance

Adiponectin levels predict mixed and non-calcified coronary atherosclerotic plaque burden. Low adiponectin levels may contribute to coronary plaque vulnerability and may thus play a role in the pathophysiology of ACS.

Introduction

Atherosclerosis is the primary cause of coronary artery disease (CAD), one of the most common causes of illness and death worldwide. There is increasing recognition that lesion composition rather than size determines the acute complications of atherosclerotic disease in humans. Several studies suggested that thin-cap fibroatheroma (non-obstructive plaques) are prone to rupture and result in acute coronary artery occlusions [1][3], whereas obstructive, calcified plaques result in clinically stable angina pectoris.

Initiation and progression of the atherosclerotic lesion are highly complex processes, and many aspects of atherogenesis remain incompletely understood. Ectopic visceral adipose tissue was linked to the pathogenesis of atherosclerosis due to secretion of a multitude of pro- and anti-atherogenic cytokines and adipokines [4]. More recently, pericardial adipose tissue (PAT) was also reported to play an important role in coronary atherosclerosis [5], presumably through paracrine and vasocrine signaling of adipokines [6].

Adiponectin is the most abundant adipokine produced by adipose tissue. Serum levels of adiponectin are markedly decreased in patients with visceral obesity and states of insulin resistance such as non-alcoholic fatty liver disease and type 2 diabetes [7], [8]. There is an ongoing debate regarding adiponectin's significance for CAD. Although experimental data do suggest an atheroprotective effect [9], existing epidemiological data connecting adiponectin and cardiovascular disease are controversial. Low adiponectin levels have been linked to the presence of CAD [10] and were shown to be a risk factor for CAD [11] and cardiovascular events [12]. Low adiponectin levels were reported to be associated with a higher risk of acute coronary syndrome, independent of other traditional metabolic and cardiovascular risk factors [13]. Low adiponectin levels were also reported to be associated with the progression of coronary artery calcification as determined by electron-beam CT [14]. Furthermore, low serum adiponectin levels were shown to be an independent predictor of the extent of CAD and coronary lesion complexity as determined by coronary angiography [15][17]. In contrast, other studies including a recent meta-analysis of 7 prospective reports on adiponectin and coronary heart disease in Western populations failed to show an association between adiponectin and incident coronary heart disease as well as secondary cardiovascular events in patients with known CAD [18], [19].

The angiographic assessment of coronary luminal stenosis has been considered a surrogate marker of the severity of atherosclerosis. However, coronary angiography has low predictive value to assess atherosclerotic plaque burden or to predict acute coronary syndrome events [20][22]. It does not allow to identify non-obstructive coronary plaques or to determine the composition of atherosclerotic plaques. Therefore, in the present study, we used dual-source multi-slice CT (DSCT)-angiography to quantitatively and qualitatively assess coronary artery plaques to test whether 1) adiponectin serum levels are associated with coronary atherosclerotic plaque burden and 2) adiponectin levels are associated with coronary atherosclerotic plaque morphology.

Results

Baseline characteristics of the study population are shown in Table 1. 303 consecutive patients with stable typical or atypical chest pain underwent DSCT-coronary angiography to exclude coronary artery stenosis.

Table 1
Baseline characteristics and CT-angiographic findings of the study population.

In 60 patients no coronary plaques could be detected. The median number of coronary plaques was 3 (IQR: 1–6; range: 0–26). The median numbers of calcified, mixed and non-calcified plaques were 1 (IQR: 0–3; range: 0–22, number of patients with calcified plaques: 154), 0 (IQR: 0–1; range: 0–10, number of patients with mixed plaques: 102) and 0 (IQR: 0–2; range: 0–9, number of patients with non-calcified plaques: 126), respectively.

Correlations and associations between adiponectin and cardiovascular risk factors

Serum adiponectin levels were positively correlated with HDL-cholesterol (HDL-C) (r = 0.32, p<0.0001) and age (r = 0.16, p = 0.005), yet negatively correlated with body mass index (BMI) (r = −0.26, p<0.0001) and triglycerides (r = −0.32, p<0.0001) (Table 2). Interestingly, adiponectin was negatively correlated with PAT volume (r = −0.24, p<0.0001). No correlation was seen with LDL-cholesterol (LDL-C) (r = 0.09, p = 0.11) and high sensitivity C-reactive protein (hsCRP) levels (r = −0.04, p = 0.49).

Table 2
Correlations and associations between adiponectin and cardiovascular risk factors.

Among demographic characteristics, smoking (p = 0.02) was associated with lower adiponectin levels. No or borderline association was seen with diabetes mellitus (p = 0.37), hypertension (p = 0.13), and family history of CAD (p = 0.05).

Adiponectin is an independent negative predictor of coronary atherosclerotic burden

In bivariate analysis, adiponectin levels were negatively correlated with total number of coronary artery plaques (r = −0.21, p = 0.0004) (Table 2). In a fully adjusted multivariate model containing age, sex, BMI, hypertension, diabetes mellitus, smoking, family history of CAD, LDL-C, HDL-C, triglycerides, hsCRP, medication and PAT volume, adiponectin levels were predictive of coronary atherosclerotic plaque burden, i.e. an increase in adiponectin levels by 27.8 µg/ml is associated with the reduction of one atherosclerotic plaque (estimate: −0.036, 95%CI: −0.052 to −0.020, p<0.0001) (Table 3). Thus, based on the range of adiponectin and the range of total plaque number, adiponectin levels account for approximately 3% of the variability in total plaque burden in our study population.

Table 3
Multivariate association of adiponectin levels with coronary atherosclerotic plaque burden.

Adiponectin is inversely associated with mixed and non-calcified coronary artery plaques

Adiponectin was negatively correlated with mixed (r = −0.20, p = 0.0007) and non-calcified plaques (r = −0.18, p = 0.003) (Table 2). No correlation was seen with calcified plaques (r = −0.05, p = 0.39). In fully adjusted multivariate models, adiponectin levels remained a negative predictor of mixed and non-calcified plaque burden. Thus, the number of mixed plaques decrease by 1 for an 11.5 µg/ml increase in serum adiponectin levels (estimate: −0.087, 95%CI: −0.132 to −0.042, p = 0.0001) (Table 4). Furthermore, an increase in adiponectin levels by 13.2 µg/ml is associated with the reduction of one non-calcified plaque (estimate: −0.076, 95%CI: −0.115 to −0.038, p = 0.0001) (Table 5). Based on the range of adiponectin and the range of mixed and non-calcified plaque numbers, adiponectin levels account for approximately 20% of the variability in mixed and non-calcified plaque burden.

Table 4
Multivariate association of adiponectin levels with mixed plaques.
Table 5
Multivariate association of adiponectin levels with non-calcified plaques.

After adjusting for traditional cardiovascular risk factors adiponectin turned out to be significantly associated with calcified plaques (Table 6). In a fully adjusted model, however, this association was lost again (estimate: −0.021, 95%CI: −0.043 to 0.001, p = 0.06).

Table 6
Multivariate association of adiponectin levels with calcified plaques.

Discussion

Our study was designed to examine the relationship of adiponectin with total coronary atherosclerotic plaque burden and atherosclerotic plaque morphology in humans. We demonstrate that 1) adiponectin levels are predictive of total coronary plaque burden, and 2) adiponectin levels are inversely correlated with the number of mixed and non-calcified plaques. No significant correlation was seen with calcified plaques. Our data suggest that the number of mixed and non-calcified plaques decrease by 1 for each 11.5 µg/ml and 13.2 µg/ml increase in serum adiponectin levels, respectively.

Pundziute et al. [23] reported that the number of coronary segments with mixed plaques as determined by MSCT was an independent predictor of acute cardiac events including cardiac death, nonfatal myocardial infarction and unstable angina requiring hospitalization. Hoffmann et al. [24] demonstrated that in contrast to calcified plaques, non-calcified plaques as determined by MSCT were consistently present in culprit lesions of patients with acute coronary syndrome. We have recently shown that rapid progression of angiographic stenosis severity occurred most frequently in coronary segments with non-calcified or predominantly non-calcified plaques as determined by MSCT [25]. Wolk et al. [13] reported that higher plasma adiponectin levels were associated with a lower risk of acute coronary syndrome, suggesting that the pathophysiological role of adiponectin may be related to the stability of atherosclerotic plaque rather than atherosclerotic burden. Our data indicate that adiponectin may reduce the number of non-calcified and mixed plaques without affecting stable calcified plaques. Consistent with these observations, Marso et al. [26] showed in a very recent study that low adiponectin levels were associated with lipid-rich yet not calcified coronary plaques in non-diabetic patients in bivariate analysis as determined by IVUS. Furthermore, Otake et al. [27] demonstrated that the necrotic core component ratio of culprit lesions as determined by IVUS in patients with acute coronary syndrome was negatively correlated with adiponectin levels in bivariate analysis. Therefore, the finding of an independent association between adiponectin and non-calcified and mixed coronary plaques may have important therapeutic and preventive implications for decreasing the risk of acute coronary events.

Although the exact mechanisms of the negative association between adiponectin and mixed and non-calcified plaques remain to be determined, several possible explanations should be considered. In addition to its beneficial effects on insulin sensitivity and lipid metabolism [28], adiponectin exerts its vasculoprotective effects through its direct actions on endothelial cells, monocytes, macrophages and other inflammatory cells, platelets and smooth muscle cells, thus modulating initiation and progression of atherosclerosis. Adiponectin augments endothelial NO production [29], [30], inhibits ox-LDL–induced endothelial ROS generation [31], suppresses the expression of endothelial adhesion molecules [32][34], attenuates leucocyte-endothelium interactions [35] and protects endothelial cells from apoptosis [36]. Furthermore, adiponectin inhibits macrophage activation [37], [38] and foam cell formation [39], promotes the clearance of early apoptotic cells by macrophages [40], inhibits smooth muscle cell proliferation [32], [41] and antagonizes the stimulatory effect of TNF-α on vascular smooth muscle cell calcification [42].

The present study has several strengths and limitations. Our data support the concept that adiponectin is an important marker in the pathogenesis of atherosclerosis since adiponectin remains significantly associated with plaque morphology in a fully adjusted multivariate model containing age, sex, BMI, hypertension, diabetes mellitus, smoking, family history of CAD, LDL-C, HDL-C, triglycerides, hsCRP, medication and PAT volume. However, since this was an association study, our study does not establish a causal relationship between adiponectin and coronary plaque morphology. Furthermore, the clinical implications of our results still need to be determined.

There are conflicting epidemiological data regarding the role of adiponectin in atherosclerosis with some studies showing strong inverse associations between adiponectin levels and CAD [10][17] and others failing to detect any association [18], [19]. Differences in study design, population characteristics and statistical adjustments may in part explain the apparent discrepancies. In addition, different methods of CAD assessment (CT-angiography or IVUS versus conventional angiography or CT-based assessment of coronary artery calcification) may yield distinct results. Adiponectin may modulate early stages of atherogenesis thus mainly affecting the development of non-calcified or mixed plaques.

In the present study adiponectin is not correlated with calcified plaques, the majority of coronary plaques in our study cohort. Therefore, although statistically highly significant, adiponectin levels are associated with a very modest decrease in total coronary plaque burden accounting for only 3% of the variability in total number of coronary plaques. In contrast, adiponectin accounts for approximately 20% of the variability in mixed and non-calcified plaque burden. Determination of the bioactive high molecular weight form of adiponectin may have possibly resulted in an even stronger association of adiponectin with plaque burden and morphology. Overall, our data emphasize the importance of additional risk factors in the pathogenesis of atherosclerosis.

Storage conditions of blood samples (e.g. storage time and temperature) were suggested to alter adiponectin levels [43], [44]. However, comparing adiponectin concentrations in serum aliquots stored for 21 and 33 months at −70°C, adiponectin levels were not significantly different (p = 0.45) suggesting that storage conditions did not impact on our results due to adequate specimen stability.

Finally, our study results may only be applicable to non-diabetic patients. Diabetics were clearly underrepresented in the present study (7% of patients). The small number of diabetic patients may also explain the lack of association between adiponectin levels and diabetes.

In summary, we demonstrate that adiponectin is inversely associated with coronary plaque burden and mixed and non-calcified plaques, suggesting an important role of adiponectin in the pathogenesis of atherosclerosis and possibly in the pathophysiology of acute coronary syndrome.

Methods

Ascertainment of Subjects

303 consecutive patients who underwent DSCT-coronary angiography for exclusion of coronary artery stenosis due to stable typical or atypical chest pain, were recruited during 20 consecutive months from March 2006 to October 2007. After providing informed written consent, study subjects were asked to complete a brief questionnaire and have blood drawn. The study protocol was approved by the Ethics Committee of the Ludwig-Maximilians-University Munich, Germany.

Dual-source multi-slice CT-coronary angiography

CT-coronary angiography was performed using a Siemens Definition scanner (Siemens Medical Solutions, Forchheim, Germany) that uses two X-ray sources for image generation. Tube voltage for CT-angiography was 120 kV for both tubes in patients with a body weight >80 kg and 100 kV for those with a weight <80 kg. Current was 560 mA with modulation, and full current between 30–50% to 80% of the cardiac cycle. Gantry rotation time was 0.33 s, and pitch 0.2–0.44 adapted to the HR. Per rotation 64 slices were generated with a collimation of 0.6 mm, leading to an isotropic voxel resolution of approximately 0.6 mm edge length and 0.2 mm3 volume. Before the scan, nitroglycerine was administered sublingually. A bodyweight-adapted volume of contrast agent (1.25 cm3/kg bodyweight, Ultravist 370, Schering, Berlin, Germany) was injected continuously at a calculated rate to achieve constant injection during 20 s. The scan was started with a delay of 5 s after the density in the aortic root exceeded a density value of 100 HU (bolus tracking). A saline flush (100 cm3 at 5 cm3/s) was applied to maintain a compact bolus. Axial images were reconstructed with 0.75 mm slice thickness and 0.5 mm increment using a medium sharp convolution kernel (B26f) and retrospective ECG gating. The reconstructions were performed in 10% steps over the entire R-R cycle using a single-segment algorithm that utilizes a quarter segment of projection data from both detectors. In atrial fibrillation, data were reconstructed in 50 ms steps.

Dual-source CT image analysis

Coronary analysis

In the first step, all reconstructed data sets were evaluated at different ECG-phases for diagnostic image quality and the optimal data set was then chosen for analysis. The DSCT datasets were evaluated by two independent investigators blinded to serum adiponectin levels using a dedicated cardiac workstation (Siemens, Leonardo Circulation).

Atherosclerotic plaques were classified as calcified, mixed or non-calcified as described previously [45]. Calcified plaques were defined as lesions with a HU value above 130. Non-calcified plaques were defined as structures clearly assignable to the vessel wall (in at least two views) with densities less than the lumen contrast. Plaques with <50% calcified plaque area were classified as mixed. The coronary tree was segmented according to the suggestions of the AHA into a 15 segment model. Each segment was further divided into a proximal and a distal segment. Each segment was then classified as containing either calcified, non-calcified, mixed or no plaque. Based on the number of diseased segments a plaque score was calculated. Adequate image quality for evaluation of coronary plaques was obtained in 281 of 303 patients.

The interobserver agreement of the 2 investigators was 95% for calcified plaques, 94% for mixed plaques, and 93% for non-calcified plaques.

Pericardial fat assessment

The same images as for the analysis of atherosclerotic plaques were used to determine PAT volume. PAT volume was measured in ml using the volume analysis software tool of the Siemens Leonardo Circulation workstation. PAT volume was determined similar to the method described by Gorter et al. [46]. We defined PAT as the adipose tissue surrounding the myocardium. The upper cut off point in the axial slices was the bifurcation of the pulmonary artery. Adequate image quality for evaluation of PAT volume was obtained in 287 of 303 patients. The interobserver agreement for PAT volume was 95%.

Laboratory procedures

Blood samples were stored in aliquots at −70°C until analysis (i.e. up to 21 months). Serum levels of adiponectin (µg/ml) were determined with a commercial enzyme-linked immunosorbent assay (R&D, Wiesbaden, Germany). To determine whether storage conditions may have affected adiponectin levels, adiponectin concentrations in aliquots stored for 21 and 33 months at −70°C from 20 patients were measured. Adiponectin levels did not differ significantly between the two timepoints (21 months: 5.6±1.2 (mean±standard deviation) µg/ml versus 33 months: 5.3±1.1 µg/ml; p = 0.45) indicating adequate specimen stability under our storage conditions.

Plasma LDL-C, HDL-C and triglycerides were measured by routine enzymatic methods. Determination of hsCRP levels was performed at the Department of Clinical Chemistry (Campus Grosshadern, University of Munich, Germany).

Statistical Analysis

Statistical analyses were performed using SAS 9.1 (Cary, NC) software. Data are reported as n or median (interquartile range). Spearman correlation and Wilcoxon two-sample test were used in the bivariate analysis of adiponectin with other variables. A generalized linear regression model was used to assess the association of adiponectin serum levels with atherosclerotic plaque burden, number of calcified plaques, mixed plaques or non-calcified plaques adjusted for age, sex, BMI, diabetes, hypertension, family history of CAD, smoking, LDL-C, HDL-C, triglycerides, hsCRP levels, medical treatment (statin, asa, plavix, marcumar, betablockers, ACE inhibitors, angiotensin-receptor blockers, diuretics, oral anti-diabetic drugs, insulin) and PAT volume - possible confounders of adiponectin levels. All tests were two-tailed with a 0.05 type I error rate.

Supporting Information

Table S1–S4

Full adjusted model (model 5) for total number of coronary plaques, mixed, non-calcified and calcified plaques

(0.05 MB DOC)

Acknowledgments

We are indebted to Elisabeth Fleischer-Brielmaier, Inge Biller-Friedmann and Kerstin Henze for expert technical assistance.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grants BR 2151/4-1 (UCB) and LE 1350/2-1 (ML) from the Deutsche Forschungsgemeinschaft. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–1672. [PubMed]
2. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–1275. [PubMed]
3. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13–18. [PubMed]
4. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–880. [PubMed]
5. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation. 2008;117:605–613. [PubMed]
6. Sacks HS, Fain JN. Human epicardial adipose tissue: A review. Am Heart J. 2007;153:907–917. [PubMed]
7. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939–949. [PubMed]
8. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. [PubMed]
9. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278:2461–2468. [PubMed]
10. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–89. [PubMed]
11. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369–1377. [PubMed]
12. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–1737. [PubMed]
13. Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2007;28:292–298. [PubMed]
14. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111:747–753. [PubMed]
15. von Eynatten M, Schneider JG, Humpert PM, Kreuzer J, Kuecherer H, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol. 2006;47:2124–2126. [PubMed]
16. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006;48:1155–1162. [PubMed]
17. Selcuk MT, Selcuk H, Temizhan A, Maden O, Saydam GS, et al. Impact of plasma adiponectin levels to the presence and severity of coronary artery disease in patients with metabolic syndrome. Coron Artery Dis. 2008;19:79–84. [PubMed]
18. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006;114:623–629. [PubMed]
19. Von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, et al. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J. 2008;29:1307–1315. [PubMed]
20. Pasterkamp G, Falk E, Woutman H, Borst C. Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making? J Am Coll Cardiol. 2000;36:13–21. [PubMed]
21. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56–62. [PubMed]
22. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157–1166. [PubMed]
23. Pundziute G, Schuijf JD, Jukema JW, Boersma E, de Roos A, et al. Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol. 2007;49:62–70. [PubMed]
24. Hoffmann U, Moselewski F, Nieman K, Jang IK, Ferencik M, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol. 2006;47:1655–1662. [PubMed]
25. Leber AW, von Ziegler F, Becker A, Becker CR, Reiser M, et al. Characteristics of coronary plaques before angiographic progression determined by Multi-Slice CT. Int J Cardiovasc Imaging. 2008;24:423–428. [PubMed]
26. Marso SP, Mehta SK, Frutkin A, House JA, McCrary JR, et al. Low Adiponectin Levels are Associated with Atherogenic Dyslipidemia and Lipid-Rich Plaque in Non-Diabetic Coronary Arteries. Diabetes Care. 2008;31:989–994. [PubMed]
27. Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, et al. Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008;101:1–7. [PubMed]
28. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes. 2005;54:795–802. [PubMed]
29. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia. 2003;46:1543–1549. [PubMed]
30. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021–45026. [PubMed]
31. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 2004;315:264–271. [PubMed]
32. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767–2770. [PubMed]
33. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004;89:765–769. [PubMed]
34. Kobashi C, Urakaze M, Kishida M, Kibayashi E, Kobayashi H, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res. 2005;97:1245–1252. [PubMed]
35. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007;117:1718–1726. [PMC free article] [PubMed]
36. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94:e27–e31. [PubMed]
37. Park PH, McMullen MR, Huang H, Thakur V, Nagy LE. Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-α (TNF-α) expression via ERK1/2 activation and Egr-1 expression: role of TNF-α in adiponectinstimulated interleukin-10 production. J Biol Chem. 2007;282:21695–21703. [PMC free article] [PubMed]
38. Zhao T, Hou M, Xia M, Wang Q, Zhu H, et al. Globular adiponectin decreases leptin-induced tumor necrosis factor-α expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol. 2005;238:19–30. [PubMed]
39. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057–1063. [PubMed]
40. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest. 2007;117:375–386. [PMC free article] [PubMed]
41. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277:25863–25866. [PubMed]
42. Son BK, Akishita M, Iijima K, Kozaki K, Maemura K, et al. Adiponectin Antagonizes Stimulatory Effect of TNF{alpha} on Vascular Smooth Muscle Cell Calcification: Regulation of Gas6-Mediated Survival Pathway by AMP-Activated Protein Kinase. Endocrinology. 2008;149:1646–1653. [PubMed]
43. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem. 2003;49:650–652. [PubMed]
44. Pischon T, Schulze MB, Rimm EB. Letter by Pischon et al regarding article, “Adiponectin and coronary heart disease: a prospective study and meta-analysis”. Circulation. 2007;115:e322. [PubMed]
45. Leber AW, Becker A, Knez A, von Ziegler F, Sirol M, et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol. 2006;47:672–677. [PubMed]
46. Gorter PM, van Lindert AS, de Vos AM, Meijs MF, van der Graaf Y, et al. Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis. 2008;197:896–903. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science